Lactadherin in Cancer Development and Progression

Subjects: Cell Biology

Contributor: Eduardo Duran, Lorena Lobos, lorena Lobos-Gonzalez

Lactadherin is a secreted glycoprotein associated with the milk fat globule membrane, which is highly present in the blood and in the mammary tissue of lactating women. Several biological functions have been associated with this protein, mainly attributable to its immunomodulatory role promoting phagocyte-mediated clearance of apoptotic cells. It has been shown that lactadherin also plays important roles in cell adhesion, promotion of angiogenesis, and tissue regeneration. On the other hand, this protein has been used as a marker of breast cancer and tumor progression. Recently, high levels of lactadherin has been associated with poor prognosis and decreased survival, not only in breast cancer, but also in melanoma, ovarian, colorectal, and other types of cancer. Although the mechanisms responsible for the tumor-promoting effects attributed to lactadherin have not been fully elucidated, a growing body of literature indicates that lactadherin could be a promising therapeutic target and/or biomarker for breast and other tumors. Moreover, recent studies have shown its presence in extracellular vesicles derived from cancer cell lines and cancer patients, which was associated with cancer aggressiveness and worse prognosis.

Keywords: lactadherin ; breast cancer ; metastasis ; exosomes ; extracellular vesicles

1. Introduction

Lactadherin: A Milk Fat Globule Protein Associated with Cancer Development

Mammals produce milk fat globules (MFG) during lactation, which can contain up to 322 proteins, depending on the species ^[1]. About 50% of these proteins correspond to mammary tissue membrane proteins. Among them, lactadherin (also known as Milk Fat Globule-Epidermal Growth Factor 8 (MFG-E8), Breast Epithelial Antigen (BA46), SED1, among others) is a secreted glycoprotein associated with the milk fat globule membrane (MFGM) ^{[1][2]}. Human lactadherin consists of one N-terminal EGF-like domain which includes residues 24–67, followed by two repeated C domains (in human lactadherin, these include residues 70–255 and 230–387, respectively) ^[1]. The EGF-like domain contains an Arg-Gly-Asp (RGD) cell adhesion sequence motif that is recognized by integrin receptors, mainly $\alpha\nu\beta3/\beta5$ ^{[3][4][5]} (**Figure 1**). In humans, the *MFGE8* gene is located in chromosome 15, and codifies a 387 residues protein. After the cleavage of the signal peptide (residues 1–23), a 43–46 kDa full-length lactadherin protein, including residues between positions 202 and 387. This gives rise to an integral protein of the MFGM that has completely lost the EGF-like domain and some of the residues of the first C-domain ^{[Δ][6]}.



Figure 1. Lactadherin structure and possible roles in physiologic and pathologic states.

It is well known that lactadherin is present in the blood of lactating women, and that is highly expressed in breast tissue ^[1]. Several functions have been associated with its structural domains, mainly involving the interaction with $\alpha\nu\beta3/\beta5$ -integrins present in macrophages and with phosphatidylserine (PS) exposed in apoptotic cells, therefore, promoting phagocytosis (efferocytosis) ^[Z]. Other important functions described for lactadherin include antiviral properties ^{[B][9]}, modulation of the innate immune system through the activation of tumor-associated macrophages ^[10], promotion of VEGF-induced angiogenesis ^[11], and tissue regeneration ^{[12][13][14][15][16][17]}.

2. Lactadherin as a Biomarker of Tumor Subtype, Progression and Metastasis

Although the expression of lactadherin was initially described in breast epithelial tissue, it has also been found in several other tissues and organs, especially in those related to the reproductive system, such as placenta, endometrium, and fallopian tubes ^{[18][19][20][21][22]}.

The most significant first advances regarding lactadherin as a tumor marker came from Ceriani and his group. They and others have extensively studied lactadherin expression in breast tumors to develop monoclonal antibodies targeting lactadherin and other proteins of the MFG, as immunotherapy against breast cancer $^{[20][23][24][25]}$. This group detected lactadherin (more precisely, human epithelial antigens, among them is lactadherin) in the sera of patients with disseminated breast cancer $^{[26]}$. After this intellectual–productive period of lactadherin-related research and its role in the biology and pathophysiology of breast cancer, there were many years without significant findings. Only since the mid-2000s, new information emerged regarding this protein involved in tumor development. Remarkably, during this time, its overexpression was also described in other types of cancer, including pancreatic cancer models $^{[27]}$, bladder cancer $^{[28]}$, ovarian cancer $^{[29]}$, oral cancer $^{[30]}$, among others $^{[31][32][33]}$.

In 2012, Carrascosa et al. analyzed gene expression public data (microarrays), and showed lactadherin overexpression both in primary tumors and in breast cancer metastases. Interestingly, its expression was associated with the absence of hormonal receptors ^[34]. Other studies have also associated lactadherin expression levels with the absence of hormonal receptors, being higher in triple negative cell lines and in triple-negative breast cancer (TNBC) biopsies ^{[35][36]}. Moreover, another recent study showed the presence of a recurrent gene fusion comprising MFGE8 and HPLN3 genes using TNBC patient genomic data. This gene fusion was much more frequent in TNBC than in other subtypes. The authors further validated the presence of the MFGE8–HPLN3 gene fusion in TNBC biopsies, and predicted the length of the encoded protein, suggesting its critical role in TNBC biology, and a possible clinical application as a new biomarker ^[37].

3. Lactadherin Role as Promotor of Tumor Progression

Lactadherin expression has been associated with the aggressiveness and progression of several types of cancer. In fact, most of the studies associated lactadherin overexpression in tumor samples with the promotion of pro-tumorigenic and pro-metastatic capacities, such as increased tumor cell proliferation, angiogenesis, migration, invasion, and epithelial-to-mesenchymal transition (EMT) $\frac{[11][27][34][38][39][40][41][42][43]}{[11][27][34][38][39][40][41][42][43]}$; processes that are related to the physiological function of this protein. In this context, several studies in the cancer field, but also in other diseases, have demonstrated the activation of commonly pro-tumorigenic signaling pathways mediated by lactadherin overexpression, such as their interaction with β 3-integrin, and the activation of the PI3K/AKT signaling $\frac{[39][42][44][45][46]}{[39][42][44][45][46]}$. On the other hand, most of the studies have not deepened in the downstream intracellular signaling triggered by lactadherin, thus leaving the field open for more complete and comprehensive studies.

3.1. Tumor Cell Survival/Proliferation and EMT

Lactadherin is able to interact with $\alpha\nu\beta3/\beta5$ -integrins through its RGD domain. This interaction allows the anchorage and rapprochement between cells (or extracellular matrix), thus favoring apoptotic cell clearance through phagocytosis ^{[2][5][7]}. On the other hand, the activation of $\beta3$ -integrin signaling can lead to the activation of pro-survival, anti-apoptotic, and prometastatic pathways through the activation of molecules such as Akt and Twist, as shown in murine melanoma studies ^[39]. This lactadherin/ $\beta3$ -integrin interaction could promote the EMT process (through PI3K/Akt, Twist); an effect that has also been observed in CRC cancer models, where lactadherin promotes the migration and invasion of tumor cells ^[42].

3.2. Lactadherin Immunomodulatory Role

Another important function of lactadherin is its immunomodulatory role, mainly as an immunosuppressive molecule ^[1]. The first reports in this topic show that lactadherin is able to bind β 3-integrin on the surface of phagocytes, mainly macrophages. In the same way, lactadherin can bind PS exposed in cells undergoing apoptosis, and promote their phagocytosis ^[Z] (**Figure 1**). Subsequent studies have shown that other cells of the immune system also express lactadherin, such as dendritic cells, mast cells, and regulatory T lymphocytes, in addition to endothelial cells that are in direct contact with blood and blood cells ^[1].

Lactadherin has also been involved in the modulation of the immune system in other types of cancer, such as oral cancer ^[30], esophageal cancer ^[31], and, recently, angiosarcoma ^[32] and a murine glioma model ^[47]. The immunomodulation in these types of cancer have been constantly associated with tumor development and bad prognosis.

4. Lactadherin as a Possible New Cancer Therapeutic Target

Although lactadherin has various regulatory physiological roles, and its expression and function have been targeted for the treatment of several other diseases (e.g., vascular and autoimmune pathologies) ^{[13][14][15][46][48][49][50]}, it has been established to be most relevant in the oncologic area. First studies by Ceriani et al. showed that an antibody cocktail, including MoAbs against HMFG components (one of them against lactadherin), worked as treatment and prevention against the engraftment of ER-positive and negative mammary tumors ^{[20][23]}. Later, this group and others published several reports using this cocktail of antibodies, including an anti-lactadherin blocking antibody, demonstrating its beneficial effect against breast tumors ^{[24][25][51]}. Subsequently, several studies reported lactadherin as a possible cancer therapeutic target ^{[28][34][38][41][43]}, either using gene therapy approaches, inhibiting its expression by siRNAs or shRNAs, or by using specific antibodies that block its function and interactions with $\alpha\nu\beta3/\beta5$ integrins ^[35].

Recently, using TCGA data and machine learning, Kothari et al. have shown that lactadherin is one out of two proteins/genes that can differentiate TNBC from non-TNBC irrespective of their heterogeneity or subtype differences ^[52]. Further affinity purification mass spectrometry and proximity biotinylation experiments identified a possible role for lactadherin in various tumor survival processes. Another study also using TCGA RNA-seq data showed that lactadherin, as well as KLK5/7 expression, are associated with COX-2 inhibitors treatment resistance in TNBC cells. Silencing of these genes markedly recovered COX-2 inhibitor sensitivity both in vitro and in vivo. Considering the difficulty in the treatment of TNBC, these results could support the possibility of using new combination therapies against TNBC involving COX-2 and lactadherin inhibition ^[53].

5. Extracellular Vesicles and Exosomes as Promotors of Breast Cancer Metastasis

Metastasis is defined as the dissemination of cancerous cells from the primary tumor, and the effective colonization of secondary target organs. It is widely accepted that intercellular communication is essential in all steps of the metastatic cascade. Exosomes are a particular subpopulation of EVs released by a variety of cell types. These exosomes are 40–200 nm in diameter, and are derived from the multivesicular endosome pathway, and can enter a recipient cell mainly through three different pathways: membrane fusion, endocytosis, or the interaction of proteins in exosomes with receptors in recipient cells ^{[54][55][56][57]}. Exosomes are thought to play important roles in intercellular communication, transferring a variety of molecules to target recipient cells. Exosomes contain several bioactive molecules, such as nucleic acids (mRNA, microRNA, DNA, and other non-coding RNAs), proteins (receptors, transcription factors, enzymes, extracellular matrix proteins), and lipids that can redirect the phenotype and function of a recipient cell ^{[57][58][59][60]}. Therefore, exosomes are emerging as local and systemic cell–cell mediators of oncogenic information that play an important role in cancer progression ^{[55][56][57][58][59][60][62]}.

In breast cancer, there is a potential use of exosomes and other EVs as promising diagnostic and therapeutic biomarkers. On the other hand, exosomes secreted by metastatic cells potentiate tumorigenic capacities of less aggressive cells acting in a paracrine manner ^{[58][59][60][61][62][63]}. Moreover, recent reports indicate that exosomes are able to condition the microenvironment, where tissue recipient cells are waiting for the advent of a tumor cell, and which in turn, are capable of promoting angiogenic mechanisms in breast cancer ^[61]. At the same time, exosomes secreted by tumor stroma can also influence tumor progression. Breast-cancer-associated fibroblasts secrete exosomes that have been shown to promote tumor mobility, invasion, and dissemination of breast cancer cells through the Wnt-planar cell polarity pathway (Wnt-PCP pathway) ^[64].

6. Role and Use of Lactadherin in EVs and Exosomes

Lactadherin expression has been reported in a variety of tissues and organs. However, its overexpression has been associated with bad prognosis and outcomes in different types of cancers. Moreover, lactadherin presence in EVs has recently been reported in several studies and databases [65][66][67], which has led to the consideration of it as a possible new marker of EVs. On the other hand, lactadherin C1C2 domains have been extensively used in EV designing and engineering. Due to its presence in EVs, and its interaction with PS (also present on EV surfaces), these domains are usually fused to a protein of interest, thus directing target protein to the EV surface [68][69][70][71]. This strategy has also been used to engineer EVs to expose anti-HER2 scFv on their EVs surface, and redirect EVs to HER2+ breast cancer cells to deliver a cargo of mRNA gene therapy ^[72]. More recently, a similar strategy was used by Kooijmans et al. to decorate EVs with EGFR-specific nanobodies fused to the C1C2 domains of lactadherin to further improve tumor cell targeting and incorporation [73]. Particularly in the case of breast tissue (normal or tumor), there are few studies describing the presence of lactadherin associated with exosomes or EVs. One of these articles indicates that lactadherin in EVs is required to transduce cellular signals from the basolateral side of adherent cells by accumulating exosomes in mammary epithelial cells [89]. However, this report did not describe the presence of lactadherin on the exosomes. Finally, recent studies by Lobos-Gonzalez et al., described the presence of lactadherin as part of the characterization of exosomes secreted by a metastatic breast cancer cell line (MDA-MB-231); however, functional experiments studying its specific and precise role were not performed [23,91]. As lactadherin has several functions, both as a cell adhesion molecule, and triggering intracellular signaling cascades, it is possible to think that it could have similar roles as part of EVs membranes of EVs cargo".

7. Conclusions

Lactadherin is present widely in human tissues, and can easily be targeted by its special multi-domain structures. Lactadherin can promote tumor formation, and prompts cancer vascular angiogenesis, survival, and EMT, regulating multiple oncogenic pathways (p63/p73, PI3K/Akt, β -catenin, Akt/Twist), which can promote cancer cell resistance to chemotherapy and host immunity suppression. However, to date, the specific roles, molecular mechanisms, and signaling pathways by which lactadherin promotes tumorigenic and metastatic properties of tumor cells, especially breast cancer cells, are not completely elucidated. Despite the interesting fact that several patents have used lactadherin as a possible tumor marker or even therapeutic target, there are no reported clinical trials in which this protein is being tested. On the other hand, it is well known that EVs and exosomes can mediate cell–cell communication, and can promote the acquisition of oncogenic and pro-metastatic properties in recipient cells. Past and recent works have shown the presence of lactadherin in EVs secreted by different cell types. However, the role of lactadherin present in EVs, more specifically, in exosomes secreted by cancer cells (or other cells in the tumor microenvironment), is still unknown. Given the importance

of this protein modulating tumor development and progression, deeper understanding on the role of lactadherin in EV- and exosome-mediated tumor progression and metastasis could be a promising focus of study in the future.

References

- 1. Sabha, B.H.; Alzahrani, F.; Almehdar, H.A.; Uversky, V.N.; Redwan, E.M. Disorder in milk proteins: Lactadherin multifun ctionality and structure. Curr. Protein Pept. Sci. 2018, 19, 983–997.
- Taylor, M.R.; Couto, J.R.; Scallan, C.D.; Ceriani, R.L.; Peterson, J.A. Lactadherin (Formerly BA46), a Membrane-Associ ated Glycoprotein Expressed in Human Milk and Breast Carcinomas, Promotes Arg-Gly-Asp (RGD)-Dependent Cell Ad hesion. DNA Cell Biol. 1997, 16, 861–869.
- 3. Larocca, D.; Peterson, J.A.; Urrea, R.; Kuniyoshi, J.; Bistrain, A.M.; Ceriani, R.L. A Mr 46,000 human milk fat globule pr otein that is highly expressed in human breast tumors contains Factor VHI-like domains. Cancer Res. 1991, 51, 4994.
- Couto, J.R.; Taylor, M.R.; Godwin, S.G.; Ceriani, R.L.; Peterson, J.A. Cloning and Sequence Analysis of Human Breast Epithelial Antigen BA46 Reveals an RGD Cell Adhesion Sequence Presented on an Epidermal Growth Factor-Like Do main. DNA Cell Biol. 1996, 15, 281–286.
- Andersen, M.H.; Graversen, H.; Fedosov, S.N.; Petersen, T.E.; Rasmussen, J.T. Functional analyses of two cellular bin ding domains of bovine lactadherin. Biochemistry 2000, 39, 6200–6206.
- Giuffrida, M.G.; Cavaletto, M.; Giunta, C.; Conti, A.; Godovac-Zimmermann, J. Isolation and characterization of full and truncated forms of human breast carcinoma protein BA46 from human milk fat globule membranes. J. Protein Chem. 1 998, 17, 143–148.
- Hanayama, R.; Tanaka, M.; Miwa, K.; Shinohara, A.; Iwamatsu, A.; Nagata, S. Identification of a factor that links apopto tic cells to phagocytes. Nature 2002, 417, 182–187.
- Newburg, D.S.; Peterson, J.A.; Ruiz-Palacios, G.M.; Matson, D.O.; Morrow, A.L.; Shults, J.; Guerrero, M.L.; Chaturvedi, P.; Newburg, S.O.; Scallan, C.D.; et al. Role of human-milk lactadherin in protection against symptomatic rotavirus infec tion. Lancet 1998, 351, 1160–1164.
- 9. Kvistgaard, A.; Pallesen, L.; Arias, C.; Lopez, S.; Petersen, T.; Heegaard, C.; Rasmussen, J.T. Inhibitory Effects of Hum an and Bovine Milk Constituents on Rotavirus Infections. J. Dairy Sci. 2004, 87, 4088–4096.
- Jinushi, M.; Chiba, S.; Yoshiyama, H.; Masutomi, K.; Kinoshita, I.; Dosaka-Akita, H.; Yagita, H.; Takaoka, A.; Tahara, H. Tumor-associated macrophages regulate tumorigenicity and anticancer drug responses of cancer stem/initiating cells. Proc. Natl. Acad. Sci. USA 2011, 108, 12425–12430.
- Silvestre, J.-S.; Théry, C.; Hamard, G.; Boddaert, J.; Aguilar, B.; Delcayre, A.; Houbron, C.; Tamarat, R.; Blanc-Brude, O.; Heeneman, S.; et al. Lactadherin promotes VEGF-dependent neovascularization. Nat. Med. 2005, 11, 499–506.
- Zhou, Y.; Bond, A.M.; Shade, J.E.; Zhu, Y.; Davis, C.-H.O.; Wang, X.; Su, Y.; Yoon, K.-J.; Phan, A.T.; Chen, W.J.; et al. Autocrine Mfge8 Signaling Prevents Developmental Exhaustion of the Adult Neural Stem Cell Pool. Cell Stem Cell 201 8, 23, 444–452.e4.
- Kamińska, A.; Enguita, F.J.; Stępień, E. Lactadherin: An unappreciated haemostasis regulator and potential therapeutic agent. Vasc. Pharmacol. 2018, 101, 21–28.
- 14. Uchiyama, A.; Yamada, K.; Perera, B.; Ogino, S.; Yokoyama, Y.; Takeuchi, Y.; Ishikawa, O.; Motegi, S.-I. Protective Effe ct of MFG-E8 after Cutaneous Ischemia–Reperfusion Injury. J. Investig. Dermatol. 2015, 135, 1157–1165.
- 15. Motegi, S.-I.; Leitner, W.; Lu, M.; Tada, Y.; Sárdy, M.; Wu, C.; Chavakis, T.; Udey, M.C. Pericyte-Derived MFG-E8 Regul ates Pathologic Angiogenesis. Arter. Thromb. Vasc. Biol. 2011, 31, 2024–2034.
- 16. Motegi, S.; Ishikawa, O. Mesenchymal stem cells: The roles and functions in cutaneous wound healing and tumor grow th. J. Dermatol. Sci. 2017, 86, 83–89.
- 17. Nakashima, Y.; Miyagi-Shiohira, C.; Noguchi, H.; Omasa, T. The Healing Effect of Human Milk Fat Globule-EGF Factor 8 Protein (MFG-E8) in A Rat Model of Parkinson's Disease. Brain Sci. 2018, 8, 167.
- Bocca, S.; Anderson, S.; Amaker, B.; Swanson, R.; Franchi, A.; Lattanzio, F.; Oehninger, S. Milk fat globule epidermal g rowth factor 8 (MFG-E8): A novel protein in the mammalian endometrium with putative roles in implantation and placent ation. Placenta 2012, 33, 795–802.
- 19. Arklie, J.; Taytor-Papadimitrou, J.; Bodmer, W.; Egar, M.; Millis, R. Differentiation antigens expressed by epithelial cells i n the lactating breast are also detectable in breast cancer. Int. J. Cancer 1981, 28, 23–29.

- Ceriani, R.L.; Peterson, J.A.; Blank, E.W. Breast Cancer Diagnosis with Human Mammary Epithelial Antigens and the P rospective Use of Antibodies against Them in Therapy. In Mechanisms of Cancer Metastasis. Developments in Oncolo gy; Honn, K.V., Powers, W.E., Sloane, B.F., Eds.; Elsevier: Amsterdam, The Netherlands, 1986; pp. 235–257.
- 21. UCSC Xena Open Access. Available online: https://xena.ucsc.edu (accessed on 13 May 2020).
- 22. Human Protein Atlas. (Shows Expression of Lactadherin mRNA and Protein in All Female Reproductive Organs). Availa ble online: https://www.proteinatlas.org/ENSG00000140545-MFGE8/tissue (accessed on 13 May 2020).
- Taylor-Papadimitriou, J.; Peterson, J.A.; Arklie, J.; Burchell, J.; Ceriani, R.L.; Bodmer, W.F. Monoclonal antibodies to epi thelial-specific components of the human milk fat globule membrane: Production and reaction with cells in culture. Int. J. Cancer 1981, 28, 17–28.
- 24. Sasaki, M.; Peterson, J.A.; Ceriani, R.L. Monoclonal antibodies against breast epithelial cell surface antigens in breast cancer therapy. Hybridoma 1983, 2, 120.
- 25. Peterson, J.A.; Zava, D.T.; Duwe, A.K.; Blank, E.W.; Battifora, H.; Ceriani, R.L. Biochemical and histological characteriz ation of antigens preferentially expressed on the surface and cytoplasm of breast carcinoma cells identified by monoclo nal antibodies against the human milk fat globule. Hybridoma 1990, 9, 221–235.
- 26. Ceriani, R.L.; Sasaki, M.; Sussman, H.; Wara, W.M.; Blank, E.W. Circulating human mammary epithelial antigens in bre ast cancer. Proc. Natl. Acad. Sci. USA 1982, 79, 5420–5424.
- 27. Neutzner, M.; Lopez, T.; Feng, X.; Bergmann-Leitner, E.S.; Leitner, W.W.; Udey, M.C. MFG-E8/lactadherin promotes tu mor growth in an angiogenesis-dependent transgenic mouse model of multistage carcinogenesis. Cancer Res. 2007, 6 7, 6777–6785.
- Sugano, G.; Bernard-Pierrot, I.; Laé, M.; Battail, C.; Allory, Y.; Stransky, N.; Krumeich, S.; Lepage, M.-L.; Maille, P.; Don nadieu, M.-H.; et al. Milk fat globule–epidermal growth factor–factor VIII (MFGE8)/lactadherin promotes bladder tumor development. Oncogene 2010, 30, 642–653.
- 29. Na, L.; Dai, C.; Yang, Y.; Wu, X.; Wang, L.; Wang, P. The expression levels and clinical significance of MFG-E8 and CD 133 in epithelial ovarian cancer. Gynecol. Endocrinol. 2020, 36, 803–807.
- Okamoto, A.; Sakakura, K.; Takahashi, H.; Motegi, S.I.; Kaira, K.; Yokobori-Kuwabara, Y.; Ishikawa, O.; Chikamatsu, K. Immunological and clinicopathological significance of MFG-E8 expression in patients with oral squamous cell carcinom a. Pathol. Oncol. Res. 2019, 26, 1263–1268.
- 31. Kanemura, T.; Miyata, H.; Makino, T.; Tanaka, K.; Sugimura, K.; Hamada-Uematsu, M.; Mizote, Y.; Uchida, H.; Miyazak i, Y.; Takahashi, T.; et al. Immunoregulatory influence of abundant MFG -E8 expression by esophageal cancer treated w ith chemotherapy. Cancer Sci. 2018, 109, 3393–3402.
- Fujiwara, C.; Motegi, S.-I.; Ohira, A.; Yamaguchi, S.; Sekiguchi, A.; Yasuda, M.; Nakamura, H.; Makiguchi, T.; Yokoo, S.; Hoshina, D.; et al. The significance of tumor cells-derived MFG-E8 in tumor growth of angiosarcoma. J. Dermatol. Sci. 2019, 96, 18–25.
- Yang, W.; Lai, Z.; Li, Y.; Mu, J.; Yang, M.; Xie, J.; Xu, J. Immune signature profiling identified prognostic factors for gastr ic cancer. Chin. J. Cancer Res. 2019, 31, 463–470.
- Carrascosa, C.; Obula, R.G.; Missiaglia, E.; Lehr, H.A.; Delorenzi, M.; Frattini, M.; Rüegg, C.; Mariotti, A. MFG-E8/lacta dherin regulates cyclins D1/D3 expression and enhances the tumorigenic potential of mammary epithelial cells. Oncog ene 2012, 31, 1521–1532.
- 35. Yang, C.; Hayashida, T.; Forster, N.; Li, C.; Shen, D.; Maheswaran, S.; Chen, L.; Anderson, K.S.; Ellisen, L.W.; Sgroi, D.; et al. The integrin alpha(v)beta(3–5) ligand MFG-E8 is a p63/p73 target gene in triple-negative breast cancers but e xhibits suppressive functions in ER(+) and erbB2(+) breast cancers. Cancer Res. 2011, 71, 937–945.
- Yu, L.; Zhao, L.; Jia, Z.; Bi, J.; Wei, Q.; Song, X.; Jiang, L.; Lin, S.; Wei, M. MFG-E8 overexpression is associated with poor prognosis in breast cancer patients. Pathol. Res. Pr. 2018, 215, 490–498.
- 37. Wang, M.-Y.; Huang, M.; Wang, C.-Y.; Tang, X.-Y.; Wang, J.-G.; Yang, Y.-D.; Xiong, X.; Gao, C.-W. Transcriptome Analy sis Reveals MFGE8-HAPLN3 Fusion as a Novel Biomarker in Triple-Negative Breast Cancer. Front. Oncol. 2021, 11, 6 82021.
- 38. Tibaldi, L.; Leyman, S.; Nicolas, A.; Notebaert, S.; Dewulf, M.; Ngo, T.H.; Zuany-Amorim, C.; Amzallag, N.; Bernard-Pier rot, I.; Sastre-Garau, X.; et al. New Blocking Antibodies Impede Adhesion, Migration and Survival of Ovarian Cancer Ce Ils, Highlighting MFGE8 as a Potential Therapeutic Target of Human Ovarian Carcinoma. PLoS ONE 2013, 8, e72708.
- Jinushi, M.; Nakazaki, Y.; Carrasco, D.R.; Draganov, D.; Souders, N.; Johnson, M.; Mihm, M.C.; Dranoff, G. Milk Fat GI obule EGF-8 Promotes Melanoma Progression through Coordinated Akt and Twist Signaling in the Tumor Microenviron ment. Cancer Res. 2008, 68, 8889–8898.

- 40. Oba, J.; Moroi, Y.; Nakahara, T.; Abe, T.; Hagihara, A.; Furue, M. Expression of milk fat globule epidermal growth factor-VIII may be an indicator of poor prognosis in malignant melanoma. Br. J. Dermatol. 2011, 165, 506–512.
- Yamada, K.; Uchiyama, A.; Uehara, A.; Perera, B.; Ogino, S.; Yokoyama, Y.; Takeuchi, Y.; Udey, M.C.; Ishikawa, O.; Mo tegi, S.-I. MFG-E8 Drives Melanoma Growth by Stimulating Mesenchymal Stromal Cell–Induced Angiogenesis and M2 Polarization of Tumor-Associated Macrophages. Cancer Res. 2016, 76, 4283–4292.
- 42. Zhao, Q.; Xu, L.; Sun, X.; Zhang, K.; Shen, H.; Tian, Y.; Sun, F.; Li, Y. MFG-E8 overexpression promotes colorectal can cer progression via AKT/MMPs signalling. Tumor Biol. 2017, 39, 1010428317707881.
- 43. Yang, Y.; Li, J.; Song, Q.; Zhu, K.; Yu, X.; Tian, Y.; Zhang, J. Reduction in milk fat globule-EGF factor 8 inhibits triple-ne gative breast cancer cell viability and migration. Oncol. Lett. 2019, 17, 3457–3465.
- 44. Xu, X.; Zhang, A.; Zhu, Y.; He, W.; Di, W.; Fang, Y.; Shi, X. MFG-E8 reverses microglial-induced neurotoxic astrocyte (A 1) via NF-κB and PI3K-Akt pathways. J. Cell. Physiol. 2018, 234, 904–914.
- 45. Li, H.; Xu, W.; Ma, Y.; Zhou, S.; Xiao, R. Milk fat globule membrane protein promotes C2C12 cell proliferation through t he PI3K/Akt signaling pathway. Int. J. Biol. Macromol. 2018, 114, 1305–1314.
- 46. Gao, Y.-Y.; Zhang, Z.-H.; Zhuang, Z.; Lu, Y.; Wu, L.-Y.; Ye, Z.N.; Zhang, X.-S.; Chen, C.-L.; Li, W.; Hang, C.-H. Recombi nant milk fat globule-EGF factor-8 reduces apoptosis via integrin β3/FAK/PI3K/AKT signaling pathway in rats after trau matic brain injury. Cell Death Dis. 2018, 9, 845.
- 47. Wu, J.; Yang, H.; Cheng, J.; Zhang, L.; Ke, Y.; Zhu, Y.; Wang, C.; Zhang, X.; Zhen, X.; Zheng, L.T. Knockdown of milk-f at globule EGF factor-8 suppresses glioma progression in GL261 glioma cells by repressing microglial M2 polarization. J. Cell. Physiol. 2019, 235, 8679–8690.
- 48. Zhuowang, G.; Chen, Y.; Wang, B.; Zhang, X.; Yan, Y.; Zhou, L.; Zhang, Y.; Xie, Y. MFGE8 attenuates Ang-II-induced at rial fibrosis and vulnerability to atrial fibrillation through inhibition of TGF-β1/Smad2/3 pathway. J. Mol. Cell. Cardiol. 202 0, 139, 164–175.
- 49. Matsuda, A.; Jacob, A.; Wu, R.; Zhou, M.; Aziz, M.; Wang, P. Milk fat globule–EGF factor VIII ameliorates liver injury aft er hepatic ischemia-reperfusion. J. Surg. Res. 2012, 180, e37–e46.
- Deng, K.-Q.; Li, J.; She, Z.-G.; Gong, J.; Cheng, W.-L.; Gong, F.-H.; Zhu, X.-Y.; Zhang, Y.; Wang, Z.; Li, H. Restoration of Circulating MFGE8 (Milk Fat Globule-EGF Factor 8) Attenuates Cardiac Hypertrophy Through Inhibition of Akt Pathw ay. Hypertension 2017, 70, 770–779.
- Ceriani, R.L.; Blank, E.W.; Peterson, J.A. Experimental immunotherapy of human breast carcinomas implanted in nude mice with a mixture of monoclonal antibodies against human milk fat globule components. Cancer Res. 1987, 47, 532– 540.
- 52. Kotari, C.; Osseni, M.A.; Agbo, L.; Ouellette, G.; Déraspe, M.; Laviolette, F.; Corbeil, J.; Lambert, J.-P.; Diorio, C.; Duroc her, F. Machine learning analysis identifies genes differentiating triple negative breast cancers. Sci. Rep. 2020, 10, 104 64.
- 53. Tian, J.; Wang, V.; Wang, N.; Khadang, B.; Boudreault, J.; Bakdounes, K.; Ali, S.; Lebrun, J.-J. Identification of MFGE8 and KLK5/7 as mediators of breast tumorigenesis and resistance to COX-2 inhibition. Breast Cancer Res. 2021, 23, 23.
- 54. Thery, C.; Zitvogel, L.; Amigorena, S. Exosomes: Composition, biogenesis and function. Nat. Rev. Immunol. 2002, 2, 5 69–579.
- 55. Andaloussi, S.; Mäger, I.; Breakefield, X.O.; Wood, M.J. Extracellular vesicles: Biology and emerging therapeutic opport unities. Nat. Rev. Drug Discov. 2013, 12, 347–357.
- Kowal, J.; Arras, G.; Colombo, M.; Jouve, M.; Morath, J.P.; Primdal-Bengtson, B.; Dingli, F.; Loew, D.; Tkach, M.; Théry, C. Proteomic comparison defines novel markers to characterize heterogeneous populations of extracellular vesicle subt ypes. Proc. Natl. Acad. Sci. USA 2016, 113, E968–E977.
- 57. Mathieu, M.; Martin-Jaular, L.; Lavieu, G.; Théry, C. Specificities of secretion and uptake of exosomes and other extrac ellular vesicles for cell-to-cell communication. Nat. Cell Biol. 2019, 21, 9–17.
- Lee, K.W.; Cho, J.A.; Park, H.; Lim, E.H. Exosomes from breast cancer cells can convert adipose tissue-derived mesen chymal stem cells into myofibroblast-like cells. Int. J. Oncol. 2011, 40, 130–138.
- 59. Gorczynski, R.M.; Erin, N.; Zhu, F. Serum-derived exosomes from mice with highly metastatic breast cancer transfer in creased metastatic capacity to a poorly metastatic tumor. Cancer Med. 2016, 5, 325–336.
- 60. Harris, D.A.; Patel, S.H.; Gucek, M.; Hendrix, A.; Westbroek, W.; Taraska, J.W. Exosomes Released from Breast Cance r Carcinomas Stimulate Cell Movement. PLoS ONE 2015, 10, e0117495.
- 61. Feng, Q.; Zhang, C.; Lum, D.; Druso, J.E.; Blank, B.; Wilson, K.F.; Welm, A.; Antonyak, M.A.; Cerione, R.A. A class of e xtracellular vesicles from breast cancer cells activates VEGF receptors and tumour angiogenesis. Nat. Commun. 2017,

8, 14450.

- 62. Hoshino, A.; Costa-Silva, B.; Shen, T.-L.; Rodrigues, G.; Hashimoto, A.; Mark, M.T.; Molina, H.; Kohsaka, S.; Di Giannat ale, A.; Ceder, S.; et al. Tumour exosome integrins determine organotropic metastasis. Nature 2015, 527, 329–335.
- Galindo-Hernandez, O.; Serna-Marquez, N.; Castillo-Sanchez, R.; Salazar, E.P. Extracellular vesicles from MDA-MB-2 31 breast cancer cells stimulated with linoleic acid promote an EMT-like process in MCF10A cells. Prostaglandins Leuk ot. Essent. Fat. Acids 2014, 91, 299–310.
- Luga, V.; Zhang, L.; Viloria-Petit, A.M.; Ogunjimi, A.A.; Inanlou, M.R.; Chiu, E.; Buchanan, M.; Hosein, A.N.; Basik, M.; Wrana, J.L. Exosomes Mediate Stromal Mobilization of Autocrine Wnt-PCP Signaling in Breast Cancer Cell Migration. Cell 2012, 151, 1542–1556.
- 65. Novikova, S.; Shushkova, N.; Farafonova, T.; Tikhonova, O.; Kamyshinsky, R.; Zgoda, V. Proteomic Approach for Searc hing for Universal, Tissue-Specific, and Line-Specific Markers of Extracellular Vesicles in Lung and Colorectal Adenoca rcinoma Cell Lines. Int. J. Mol. Sci. 2020, 21, 6601.
- Pathan, M.; Fonseka, P.; Chitti, S.V.; Kang, T.; Sanwlani, R.; Van Deun, J.; Hendrix, A.; Mathivanan, S. Vesiclepedia 20 19: A compendium of RNA, proteins, lipids and metabolites in extracellular vesicles. Nucleic Acids Res. 2019, 47, D516 –D519.
- 67. Véron, P.; Segura, E.; Sugano, G.; Amigorena, S.; Théry, C. Accumulation of MFG-E8/lactadherin on exosomes from im mature dendritic cells. Blood Cells Mol. Dis. 2005, 35, 81–88.
- 68. Kenari, A.N.; Cheng, L.; Hill, A.F. Methods for loading therapeutics into extracellular vesicles and generating extracellul ar vesicles mimetic-nanovesicles. Methods 2020, 177, 103–113.
- 69. Miyasaka, K.; Hanayama, R.; Tanaka, M.; Nagata, S. Expression of milk fat globule epidermal growth factor?8 in immat ure dendritic cells for engulfment of apoptotic cells. Eur. J. Immunol. 2004, 34, 1414–1422.
- Zeelenberg, I.S.; Ostrowski, M.; Krumeich, S.; Bobrie, A.; Jancic, C.; Boissonnas, A.; Delcayre, A.; Le Pecq, J.-B.; Com badière, B.; Amigorena, S.; et al. Targeting Tumor Antigens to Secreted Membrane Vesicles In vivo Induces Efficient An titumor Immune Responses. Cancer Res. 2008, 68, 1228–1235.
- 71. Komuro, H.; Kawai-Harada, Y.; Aminova, S.; Pascual, N.; Malik, A.; Contag, C.H.; Harada, M. Engineering Extracellular Vesicles to Target Pancreatic Tissue In Vivo. Nanotheranostics 2021, 5, 378–390.
- 72. Wang, J.H.; Forterre, A.V.; Zhao, J.; Frimannsson, D.O.; Delcayre, A.; Antes, T.J.; Efron, B.; Jeffrey, S.S.; Pegram, M. D.; Matin, A.C. Anti-HER2 scFv-Directed Extracellular Vesicle-Mediated mRNA-Based Gene Delivery Inhibits Growth of HER2-Positive Human Breast Tumor Xenografts by Prodrug Activation. Mol. Cancer Ther. 2018, 17, 1133–1142.
- 73. Kooijmans, S.A.A.; Gitz-Francois, J.J.J.M.; Schiffelers, R.M.; Vader, P. Recombinant phosphatidylserine-binding nanob odies for targeting of extracellular vesicles to tumor cells: A plug-and-play approach. Nanoscale 2018, 10, 2413–2426.

Retrieved from https://encyclopedia.pub/entry/history/show/56868